InvestorsHub Logo
Followers 41
Posts 5377
Boards Moderated 0
Alias Born 11/15/2013

Re: Investor2014 post# 436992

Wednesday, 10/25/2023 4:16:40 PM

Wednesday, October 25, 2023 4:16:40 PM

Post# of 459967
Not the way I read the pr wording "we are also on track" We also look forward to presenting in an upcoming major publication the complete dataset of the Phase 2b/3 Alzheimer’s disease trial of ANAVEX®2-73 (blarcamesine), a potential next-generation precision medicine convenient once daily oral Alzheimer’s disease treatment,” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. "We are also on track within our neurodevelopmental precision medicine Rett syndrome program to release top-line data of ANAVEX®2-73-RS-003 Phase 2/3 EXCELLENCE pediatric clinical trial in the current quarter of 2023.”

We shall see.

Freedom is not free.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News